Therapeutic angiogenesis - Devising new strategies based on past experiences
Therapeutic angiogenesis - Devising new strategies based on past experiences
复制标题
DOI：
10.1007/s00395-004-0447-x
复制
发表时间：
2004-03-01
影响因子：
9.5
通讯作者：
Sim, ESK
中科院分区：
文献类型：
--
作者：
Lei, Y;Haider, HK;Sim, ESK
治疗性血管生成通过补充和支持血管生成的内在过程来改善组织缺血。除了直接给药血管生成生长因子蛋白外，注射裸DNA、非病毒载体和携带血管生成基因的病毒载体也被使用。一种新的方法是通过细胞介导的基因转移来实现治疗性血管生成。携带外源性基因编码血管生成因子的基因调节细胞和具有分泌血管生成细胞因子的固有能力的细胞，如骨髓干细胞、胚胎干细胞和内皮祖细胞，已被用于实现血管再生。本文结合文献详细讨论了使用VEGF和细胞血管生成的概念的临床前研究和i /II期人体试验的证据，并分析了这些方法作为治疗缺血性心脏病的临床治疗策略的问题和注意事项。
Therapeutic angiogenesis improves tissue ischemia by supplementing and supporting the intrinsic process of angiogenesis. Besides direct administration of angiogenic growth factor proteins, injection of naked DNA, non-viral vectors and viral vector constructs carrying angiogenic genes have been used. A novel approach is to achieve therapeutic angiogenesis through cell mediated gene transfer. Genetically modulated cells carrying exogenous genes encoding for angiogenic factors and the cells with inherent ability to secrete angiogenic cytokines, such as bone marrow stem cells, embryonic stem cells and endothelial progenitor cells, have been used to achieve revascularization.This review discusses proof of the concept pre-clinical studies and phase-I/II human trials using VEGF, and cellular angiogenesis at length in the light of the literature and analyzes the problems and considerations of these approaches as a treatment strategy in the clinical perspective for the treatment of ischemic heart disease.